Compare Guardant Health Inc. Common Stock (GH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Guardant Health Inc. Common Stock trades at $163.01 (market cap $21.74B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Guardant Health Inc. Common Stock is far larger — about 6× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 3 Days and Organon & Co. Common Stock for 0 Days on average.
| GH | OGN | |
|---|---|---|
Market Cap | $21.74B | $3.62B |
Volume | 1,297,295 | 2,892,999 |
Sector | Health | Health |
52-Week High | $187.22 | $13.81 |
52-Week Low | $64.19 | $5.70 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $22.38B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
